Cytokinetics (CYTK) Given a $20.00 Price Target by HC Wainwright Analysts

Cytokinetics (NASDAQ:CYTK) received a $20.00 price objective from analysts at HC Wainwright in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 108.33% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Cantor Fitzgerald reissued a “hold” rating and issued a $10.00 target price on shares of Cytokinetics in a report on Wednesday. Needham & Company LLC cut shares of Cytokinetics from a “strong-buy” rating to a “buy” rating and cut their target price for the stock from $22.00 to $12.00 in a report on Wednesday, November 29th. TheStreet cut shares of Cytokinetics from a “c” rating to a “d” rating in a report on Friday, October 27th. JMP Securities reaffirmed an “outperform” rating and set a $13.00 price target (down previously from $17.00) on shares of Cytokinetics in a report on Tuesday, November 21st. They noted that the move was a valuation call. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $18.00 price target on shares of Cytokinetics in a report on Tuesday, November 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $17.91.

Shares of Cytokinetics (CYTK) traded up $0.80 during midday trading on Friday, reaching $9.60. 420,697 shares of the company’s stock were exchanged, compared to its average volume of 488,592. The company has a quick ratio of 7.60, a current ratio of 7.60 and a debt-to-equity ratio of 0.14. Cytokinetics has a 1 year low of $7.00 and a 1 year high of $17.20. The company has a market capitalization of $564.32, a PE ratio of -5.78 and a beta of 1.61.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.64) by $0.04. Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 62.64%. The firm had revenue of $6.18 million for the quarter, compared to analysts’ expectations of $5.35 million. research analysts anticipate that Cytokinetics will post -2.4 earnings per share for the current year.

In related news, CEO Robert I. Blum sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $13.51, for a total transaction of $67,550.00. Following the sale, the chief executive officer now owns 70,180 shares of the company’s stock, valued at $948,131.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Fady Ibraham Malik sold 7,321 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $13.39, for a total value of $98,028.19. Following the sale, the executive vice president now directly owns 47,540 shares in the company, valued at approximately $636,560.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 19,290 shares of company stock worth $245,084. Corporate insiders own 7.20% of the company’s stock.

A number of large investors have recently made changes to their positions in CYTK. Janus Henderson Group PLC bought a new stake in Cytokinetics during the second quarter worth approximately $32,488,000. Vanguard Group Inc. raised its holdings in Cytokinetics by 59.9% during the second quarter. Vanguard Group Inc. now owns 3,117,496 shares of the biopharmaceutical company’s stock worth $37,721,000 after purchasing an additional 1,168,151 shares in the last quarter. Pinnacle Associates Ltd. bought a new stake in Cytokinetics during the third quarter worth approximately $14,628,000. Wasatch Advisors Inc. raised its holdings in Cytokinetics by 139.1% during the fourth quarter. Wasatch Advisors Inc. now owns 1,679,778 shares of the biopharmaceutical company’s stock worth $13,690,000 after purchasing an additional 977,106 shares in the last quarter. Finally, State Street Corp raised its holdings in Cytokinetics by 79.6% during the second quarter. State Street Corp now owns 1,674,335 shares of the biopharmaceutical company’s stock worth $20,259,000 after purchasing an additional 741,909 shares in the last quarter. 73.61% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/20/cytokinetics-cytk-given-a-20-00-price-target-by-hc-wainwright-analysts.html.

About Cytokinetics

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Analyst Recommendations for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply